Teleflex (TFX) AI Stock Analysis

Company Guidance

Teleflex updated its 2026 guidance with pro forma adjusted constant‑currency revenue growth narrowed to 3.5%–4.5% (down from 4.5%–5.5%), raised full‑year adjusted EPS to $6.90–$7.20 (prior $6.25–$6.55) and continues to target an adjusted operating margin of ~19% for 2026 (Q2 adj. operating margin was 19.6% and adj. gross margin 61.7%; management’s steady‑state margin target is ~23%); Q2 adj. EPS was $1.76, Q2 adj. net interest expense was $26.5M and FY net interest expense is now expected at ~ $85M (vs. prior ~$105M), the adjusted tax rate is guided to ~12.25% (vs. ~13.5% prior), and shares outstanding are modeled at ~43.3M (excludes the upcoming $250M ASR). On capital allocation and balance sheet metrics, the OEM divestiture generated roughly $1.5B of proceeds (~$1.25B estimated after‑tax) used to pay down a $700M term loan, pro forma net leverage post‑OEM is ~1.9x (quarter‑end net leverage ~2.8x), the company remains committed to a $1.0B buyback program (completed $250M in Q2 repurchasing ~1.9M shares at an average $130.85 and commencing an additional $250M ASR) and an $800M debt reduction goal, and management expects meaningful margin, interest expense and EPS improvement in 2027; modeling assumptions also include an FX tailwind of ~ $14M to 2026 revenue, R&D at 7.9% of sales in H1, ~ $50M of annual pretax restructuring savings by mid‑2028, and no assumed benefit in 2026 guidance from tariff refunds (~$15M applicable to 2026; total expected cash refunds ~ $39M) or proceeds from the pending Acute Care/Interventional Urology divestitures.